Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process.
Rapid Commun Mass Spectrom
; 16(12): 1225-31, 2002.
Article
em En
| MEDLINE
| ID: mdl-12112275
ABSTRACT
Throughput for early discovery drug metabolism studies can be increased with the concomitant acquisition of metabolite screening information and quantitative analysis using ultra-fast gradient chromatographic methods. Typical ultra-fast high-performance liquid chromatography (HPLC) parameters used during early discovery pharmacokinetic (PK) studies, for example, employ full-linear gradients over 1-2 min at very high flow rates (1.5-2 mL/min) on very short HPLC columns (2 x 20 mm). These conditions increase sample throughput by reducing analytical run time without sacrificing chromatographic integrity and may be used to analyze samples generated from a variety of in vitro and in vivo studies. This approach allows acquisition of more information about a lead candidate while maintaining rapid analytical turn-around time. Some examples of this approach are discussed in further detail.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biofarmácia
/
Microssomos Hepáticos
/
Biotransformação
/
Química Farmacêutica
/
Cromatografia Líquida de Alta Pressão
/
Hepatócitos
/
Espectrometria de Massas por Ionização por Electrospray
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Diagnostic_studies
/
Screening_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Rapid Commun Mass Spectrom
Ano de publicação:
2002
Tipo de documento:
Article